Cargando…
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
BACKGROUND: Hyperinsulinemia associated with pituitary pars intermedia dysfunction (PPID) and/or equine metabolic syndrome is well documented to put horses at high risk of laminitis. While dietary control of simple sugars and starch is the most effective therapy to control hyperinsulinemia, some hor...
Autores principales: | Kellon, Eleanor M., Gustafson, Kathleen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of Veterinary Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473365/ https://www.ncbi.nlm.nih.gov/pubmed/36118716 http://dx.doi.org/10.5455/OVJ.2022.v12.i4.14 |
Ejemplares similares
-
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
por: Kellon, Eleanor M., et al.
Publicado: (2023) -
Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014) -
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019) -
Possible dysmetabolic hyperferritinemia in hyperinsulinemic horses
por: Kellon, Eleanor M., et al.
Publicado: (2019) -
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)